Susanne Staer

This author has written 413 articles

Triphase signs collaboration and option agreement with Celgene Corporation, leading innovator of cancer therapies

MI portfolio company actively seeking additional products for licensing and development

Triphase-logo-WebTORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.

Triphase Accelerator’s announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing.

Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the time and expense between an investigational new drug application and “proof-of-concept” at Phase II.

Triphase, spun out of the Ontario Institute for Cancer Research (OICR), develops and advances late pre-clinical, Phase I or early Phase II potential products. Triphase and its founding investors are in a position to take advantage of the excellent research and development capabilities in the Toronto healthcare and innovation ecosystem.

The Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation Ventures Trust, and MaRS Phase II Investment Trust, are all Toronto-based equity investors in Triphase.

After company formation, Triphase entered into a strategic relationship with Celgene Corporation. Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept (POC), plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.

Continue Reading

WaveCheck’s Crowdfunding Campaign Featured on CTV National News and Canada AM

Indiegogo campaign raised $53,390 from over 500 worldwide donors

Screen Shot 2013-12-18 at 9.40.42 AM
WaveCheck co-inventor, Dr. Gregory Czarnota, appeared on CTV National News on December 15.

CTV National News featured WaveCheck’s crowdfunding campaign on December 15 in a report by Avis Favaro. The report included an interview with MaRS Innovation’s President and CEO, Dr. Raphael Hofstein (at the 1:37 mark).

William Tran, a researcher associated with the project at Sunnybrook Health Sciences Centre, was also interviewed on Canada AM on December 16.

WaveCheck, which closed its campaign December 4, was invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Prof. Michael C. Kolios of Ryerson University. WaveCheck uses ultrasound technology to show people with breast cancer if their chemotherapy is working within weeks.

While the Indiegogo campaign has concluded, Sunnybrook Foundation is now accepting donations flagged “WaveCheck” on behalf of the researchers through its website. 

At campaign close, WaveCheck ranked in the top 0.005 per cent of health-related campaigns on Indiegogo, and was covered by CBC television and Metro Morning, the Toronto Star, Sing-Tao and MedCity News. 

Continue Reading

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the market.

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Read the original release via The National Post or in French. MaRS Innovation’s November 25 announcement about the partnership is also available.

This story was covered by GEN: Genetic Engineering Biotechnology News.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

Continue Reading

MaRS Innovation President and CEO Named to Ontario Health Innovation Council

Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell

On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.

Screen Shot 2013-12-18 at 4.33.09 PM
Members of the Ontario Health Innovation Council, including MaRS Innovation’s president and CEO Dr. Raphael Hofstein (third from left), pose after the initial announcement.

By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale.

Continue Reading

Yonge Street Media Highlights MaRS Innovation Bioprinter Project

MI Project Manger Fanny Sie discusses Toronto’s impact on 3D printing landscape

Fanny-Sie-web-7227
MaRS Innovation’s Fanny Sie is project manager for the Bioprinter, a 3D printer that can print on organic material.

In a December 4 article, part of a feature series on technology in Toronto, Yonge Street Media reporter Andrew Seale highlights the creative and innovative technological work surrounding the 3D printing and cyber security sectors in the city.

MaRS Innovation’s Fanny Sie is managing business development for the Bioprinter, a 3D printer using University of Toronto technology that’s capable of printing on organic material, including skin.

By printing on skin, the cost of treating burns on the body could be reduced.

Here’s an excerpt from the article (links and emphasis ours):

“Cells are very intelligent, you just have to be able to put them close enough to one another in order for them to take over,” says Sie adding that some of the research is a partnership with the Sunnybrook Health Sciences Centre and Research Institute.

Continue Reading

CBC News’ “The National” Features Granata Decision Systems

Amanda Lang interviews U of T prof and co-founder Craig Boutilier in segment on innovative start-ups and Canada’s future

Granata Decision System logo Nov 2013Following an appearance on the CBC’s “Lang and O’Leary Exchange” on November 28, MaRS Innovation UTEST company, Granata Decision Systems, appeared on CBC news “The National.” The segment included an interview with Amanda Lang.

Watch Boutilier’s interview with Lang for “The National” on CBC’s website. 

Screen Shot 2013-12-02 at 4.49.56 PM
Granata Decision Systems’ Co-Founder and University of Toronto Professor Craig Boutilier gives his pitch at a OneEleven investor session. Boutilier and Granata were featured on CBC News’ “The National.”

Founded by Craig Boutilier and Tyler Lu, Granata Decision Systems is one of the first six companies incubated through the UTEST program for early-stage technologies, jointly administered by MaRS Innovation and the University of Toronto.

Granata is one of eight companies to join OneEleven’s accelerator program for companies tackling big data problems.

Their software allows marketers to optimize the effectiveness of their campaigns.

The segment features co-founder Craig Boutilier’s pitch at an invitation-only investor gathering at OneEleven to secure funding to further the success of Granata Decision Systems.

Continue Reading

Lang & O’Leary Exchange features Granata Decision Systems

UTEST company makes cameo through launch of OneEleven, Toronto’s new data-driven accelerator for entrepreneurs

Granata Decision System logo Nov 2013CBC’s Lang & O’Leary Exchange featured Granata Decision Systems, one of the first UTEST companies incubated through that program for early-stage technologies by MaRS Innovation and the University of Toronto, in their program on Wednesday, November 28, 2013.

Granata founders Tyler Lu (left) and Craig Boutilier on the Lang & O'Leary Exchange
Granata founders Tyler Lu (left) and Craig Boutilier made a cameo on CBC’s Lang & O’Leary Exchange November 28, 2013.

The data-driven company is one of eight to join the inaugural cohort for OneEleven, a new accelerator funded by OMERS Ventures, the Ontario Centres of Excellence, Ryerson University and other industry partners to support mature, sophisticated entrepreneurs tackling big data problems.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top